160 The risks occur at doses lower than the usual efficacious dose of these medications for anxiety disorders. Thus, these medications do not just have a tight therapeutic index, they have a reverse index

(dose for harms lower than dose for benefits) with increasing aging. For this reason, they should be considered short-term adjuncts to treatment, with long-term use only as a last resort. Two small RCTs115,161 provided important feasibility data and preliminary evidence of the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of older adults with anxiety disorders, predominantly GAD. As a result, one of us (EJL) led the Inhibitors,research,lifescience,medical first and, to our knowledge, only namely full-scale RCT of an SSRI for acute treatment of late-life anxiety disorders.137 We randomized 177 older adults with GAD to the SSRI escitalopram, flexibly dosed Inhibitors,research,lifescience,medical at 10 to 20 mg daily, or placebo for 12 weeks. Escitalopram was shown to be efficacious, with greater cumulative response (69% vs 51%,P=0.03)

Inhibitors,research,lifescience,medical and greater improvements in worry severity and role function. The effect size for most clinical outcome measures was in the low-medium range. A reasonable conclusion from this full-scale study, together with the pilot studies, is that SSRIs are efficacious but show the same disappointing Inhibitors,research,lifescience,medical effect sizes as in studies of young adults (or older adults with depression).162 There are caveats to this conclusion: first, a single relatively small full-scale study is unlikely to be adequate for clarifying the extent of benefits for any treatment (although, as mentioned previously, we are unaware of any current efforts for another); perhaps Inhibitors,research,lifescience,medical the effect size of SSRIs is higher, or lower, than we found in that study. Second, all of these studies suffer the limitations of the measures used in anxiety trials, such as the Hamilton Anxiety Scale163 and Penn State

Worry Questionnaire. Finally, clinical symptomatology is not the only important outcome of late-life anxiety disorder treatment. In fact, it may be the least important, as patients are typically more concerned about their more info quality AV-951 of life and their systemic and (in particular) cognitive health, such as memory decline. In that study, we measured quality of life (which improved, albeit modestly, more with escitalopram than placebo) and also cognitive health, using neuropsychological testing as a proxy.164 We found that improvement in late-life GAD was associated with significant improvements in a variety of cognitive measures; however, patients randomized to escitalopram showed greater improvement than those randomized to placebo in only one neuropsychological testing – a sorting task that is a proxy for some aspects of executive function.